• Experiment 1: 2 month-old mice received Scl peptide (iv, 1mg/kg/d ) or muScl (s.c 0.05 mg/kg/d) or veh for 3 weeks.
1) Sclerostin agonist (Scl) was associated with a modest increase of whole body BMD and trabecular BV/TV whereas it decreased muscle mass.
2) Sclerostin antagonist (muScl) had inconsistent effects on bone depending on way and dose administration but increased muscle mass.
3) These preliminary observations suggest a new role of circulating sclerostin in the regulation of muscle mass. 
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